Randomized clinical trials (RCTs) of ≥16 weeks' duration comparing GLP-1 RAs vs basal insulins in adults with type 2 diabetes inadequately controlled with oral antihyperglycemic drugs were included. Data on the change from baseline to 26 weeks (AE10 weeks) of treatment in hemoglobin A1c (HbA1c) and weight, as well as the proportion of patients experiencing hypoglycaemia, were extracted. Fixed-effect pairwise meta-analyses were conducted where data were available from ≥2 studies. Interpretation of the analysis of hypoglycaemia was limited by inconsistent definitions and reporting. Because of the limited number of available studies sensitivity analyses to explore heterogeneity could not be conducted.
The clinical effectiveness and safety of GLP-1 RAs compared to each other and to oral antihyperglycemic drugs (OAD) have been assessed in several meta-analyses. [9] [10] [11] However, the positioning of GLP-1 RAs within the treatment paradigm is at the point when the use of basal insulin might also be considered; therefore, there is an increasing desire to understand the similarities and differences between GLP-1 RAs and basal insulins. Although such comparisons have been published, [11] [12] [13] [14] [15] [16] they all have limitations to consider. Wang et al. 15 do not include the two new agents (dulaglutide and albiglutide) and, although Karagiannis et al. 10 do include the new treatments, their analysis is limited to only once-weekly GLP-1 RAs. Liu et al. 13 on the other hand, pooled all GLP-1 RAs together when comparing to insulin glargine. Such pooling assumes, a priori, that all GLP-1 RAs are similar in efficacy and pharmacodynamic profile, which is not the case as demonstrated in head-to-head studies. 17, 18 More recently, Zaccardi et al. 16 conducted an analysis where GLP-1 RAs were considered independently, but basal insulins were pooled, again making an a priori assumption that all basal insulins have the same efficacy and pharmaocodynamic profile. Pooling also discounts the heterogeneity between GLP-1 RA trials regarding background therapy and drug dosage; as such, it is imperative that heterogeneity using appropriate measures is assessed prior to combining treatments for analytical purposes. To this end, to evaluate the clinical efficacy of GLP-1 RAs, by type, vs basal insulins, we conducted a systematic review of the literature and a series of paired meta-analyses to assess the differences in glycaemic control, weight change and the risk of hypoglycaemia in adults with type 2 diabetes.
| MATERIALS AND METHODS

| Data sources and searches
MEDLINE (including Epub ahead of print and In-process citations), EMBASE and the Cochrane Central Register of Controlled Trials
(CENTRAL) databases were searched from database inception to September 9, 2016. The searches were limited to peer-reviewed studies in the English language. Separate search strategies were designed for each database (MEDLINE strategy is included in Appendix S1, Supporting Information 
| Study selection
Included RCTs were selected based on predefined eligibility criteria using the population, intervention, comparators, outcomes and study design (PICOS) framework. Eligibility criteria included: (1) 
| Data extraction and quality assessment
Data extraction was performed by a single experienced data extractor into a customized spreadsheet; key fields were validated by a second extractor. Discrepancies were resolved as described previously for study selection. The extraction form was designed to collect data reporting study design features, baseline patient demographics and clinical characteristics, treatment arm details, efficacy (glycated hemoglobin [HbA1c], weight) and safety outcomes (hypoglycemia, gastrointestinal adverse events).
Endpoints at week 26 (AE10 weeks) were extracted and reported.
If data at week 26 were unavailable, the data closest to week 26 between weeks 16 and 36 were included. For trials that presented endpoints in graph format only, values were derived by digitizing the graph, using the WebPlotDigitizer program available online (http:// arohatgi.info/WebPlotDigitizer/app/). This was necessary for 4 studies. [19] [20] [21] [22] A risk assessment of bias was performed for each included RCT using the Cochrane Collaboration's tool. 23 Two reviewers independently assessed the quality of each included RCT. SD was not reported, it was imputed from other available information (eg, SE or 95% CI), using the prognostic method described by Ma et al. 24 Where sample sizes for HbA1c and weight outcomes were not reported, the intention-to-treat (ITT) population was assumed.
| Data synthesis and statistical analysis
Where sample sizes for hypoglycaemia endpoints were not reported, if available, the safety population was assumed; otherwise the ITT population was assumed.
The meta-analyses were conducted using the "meta" statistical package in R version 3.1.3. 25 To understand the difference between GLP-1 RAs and basal insulins by drug, fixed-effect pairwise metaanalyses using the frequentist approach were conducted for the changes in HbA1c and weight, and the occurrence of hypoglycaemia outcomes. Random effects analysis were considered where appreciable statistical heterogeneity was observed. However, when a small number of studies are available for analysis, as was the case for this
analysis, random effects analysis shows poor precision of betweenstudy variance, and are therefore not appropriate. 26 In keeping with the Cochrane handbook, meta-analyses were conducted where data were available for at least 2 separate trials with the same treatments. 27 If data for a treatment were identified in only 1 trial, metaanalysis was not conducted; however, the trial results are shown. 
| RESULTS
The Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) flow diagram documenting the RCT selection process is provided in Figure 1 . A total of 2694 articles were identified, of which 19 articles describing 15 RCTs were eligible for inclusion in the systematic literature review. Key study and baseline characteristics, including background therapy, are presented in Abbreviations: BG, biguanine; BMI, body mass index; HbA1c, glycated hemoglobin; MET, metformin; SD, standard deviation; SU, sulfonylurea; TZD, thiazolidinedione.
1
The majority of participants received exenatide 10 μg twice daily.
2
Trial conducted in a Japanese population.
3
Insulin glargine arm: MET = 99.6%, SU = 67.5%, SUs taken by 60% of participants at baseline and reduced to 49% at 24 weeks, liraglutide arm: MET = 99.8%, SU = 68.3%, SUs taken by 63% of participants at baseline and reduced to 48% at 24 weeks. SUs were reduced or discontinued at investigators discretion.
or 
| Risk of bias
The risk of bias for all trials included is presented in Figure S1 , Sup- 21, 28 to be performed, only 1 study reported both doses of dulaglutide (0.75 and 1.5 mg). 21 In the absence of another study with the 1.5 mg dose, a pair-wise analysis for this dose could not be per- Table S3 , Supporting Information. Figure 3B .
| Body weight
Out of the 15 studies that reported data at week 26 (AE10 weeks), 11 RCTs reported data for severe hypoglycaemia. Meta-analyses of severe hypoglycaemia were not conducted because of the limited events observed; 3 studies reported no events in both arms [28] [29] [30] and 5 studies reported no events in one arm. 19, 31, 35, 36, 39 The numbers and proportions of patients experiencing an episode of hypoglycaemia or an episode of severe hypoglycaemia, and the definitions of hypoglycaemia and severe hypoglycaemia as described by the authors are presented in Table S5 , Supporting Information.
| Gastrointestinal events
Meta-analyses of gastrointestinal events were not conducted as reporting across studies was insufficient to allow meaningful analyses (data not shown).
| DISCUSSION
The meta-analyses show statistically significant reductions in HbA1c (Figure 2) . 21 With lixisenatide, a weight reduction was observed compared to insulin glarine, but HbA1c reduction was greater with glargine ( Figure 2) . 35 With albiglutide, although there was weight reduction when compared with insulin glargine, HbA1c reduction was not different from insulin glargine (Figure 2) . 22 This finding is not unexpected, however, as albiglutide was inferior in glycaemic lowering efficacy when compared to liraglutide, which in this meta-analysis also did not have a statistically significant HbA1c reduction when compared to insulin glargine. identified by the American Diabetes Association. 40 Moreover, there were only limited data available for severe hypoglycaemia, and where
Effect of GLP-1 RA compared to basal insulin at 26 weeks (AE10 weeks) on hypoglycemia, odds ratio (A), and proportion (%) (B). Abbreviations: CI, confidence interval; GLP-1 RA, glucagon-like peptide-1 receptor agonist; OR, odds ratio; prop, proportion. *Twice daily; **once weekly. †At baseline, the majority of patients in each treatment group (exenatide 84.7%; insulin glargine 86.2%) were taking SUs. † †At baseline, 70.0% and 30.0% of patients in both arms were receiving MET and MET + SU, respectively. One in four patients had a reduction in SU dose. ‡SU dosage was reduced or discontinued at the physician's discretion. SUs were initially taken by 60.0% of those receiving insulin glargine and by 63.0% receiving liraglutide. At 24 weeks, 49.0% and 48.0%, respectively, were still taking them. ‡ ‡At baseline, 94.0% in the liraglutide arm and 95.0% in the insulin glargine arm were receiving SU. ‡ ‡ ‡The majority of the patients in the dulaglutide group (65.0%) and insulin glargine group (63.0%) received SU at baseline. In the dulaglutide and insulin glargine groups, 13/117 (11.1%) and 11/114 (9.6%) patients, respectively, decreased their concomitant SU dose from baseline as a result of hypoglycemia. §Figure includes only insulin glargine trials to highlight the differences in proportions of patients experiencing hypoglycemic events between trials, which may be due to variations in insulin titration and background therapies. data were present, the event rates were too low to yield clinically meaningful interpretation; as such, a meta-analysis for severe hypoglycaemia was not conducted. However, it is important to note that the outcome "hypoglycaemia" reported in this article also included "severe hypoglycaemia".
It is pertinent that we acknowledge the effect that insulin titration may have had on the results for hypoglycaemia. The impact of insulin titration was most apparent in the RCT conducted by D'Alessio et al. 36 which compared once-daily liraglutide 1.8 mg and insulin glargine with an aggressive up-titration of insulin glargine that resulted in a mean insulin dose of 52 units/d at study end (Table S1 Although our analysis attempted to minimize heterogeneity among studies by ensuring that treatment regimens and outcome time points were consistent, and the systematic review eligibility criteria specifying that background therapy must be received concurrently with study medication, any OAD was allowed as background therapy. However, because of the limited evidence base, heterogeneity was observed among studies, leading to uncertainty concerning the estimates. Table 1 clearly indicates that background therapy varied among the included studies, which could also have impacted the results. Whilst MET is largely weight neutral and has a low risk of hypoglycaemia associated with it, both SU and TZD treatments are associated with weight gain, which should be considered when interpreting results. In addition, SUs carry a moderate risk of hypoglycaemia, which is of particular importance because basal insulin is also associated with weight gain and an increased risk of hypoglycaemia. 42 Although sensitivity analyses can be conducted to assess the impact of differing background therapies, it
was not possible in this study because most meta-analyses included only 2 trials, a number insufficient for a meaningful sensitivity analysis.
As the analyses for the present study were being conducted, a systematic review and meta-analysis of once-weekly GLP-1 RAs was published. 10 However, the current study has several important differences from that study and other previously published analyses. Our research question was more specific than that posed by previous ana- 43 Another recently published pairwise and network metaanalysis sought to understand the benefits and harms of onceweekly GLP-1 RAs. 16 However, that analysis considered only once-weekly GLP-1 RAs and was conducted primarily to assess the cardiometabolic efficacy and adverse effects of GLP-1 RAs and not the comparison to basal insulin in the treatment paradigm, 16 as we did in our study.
There are several limitations in the current systematic literature review and meta-analysis that should be acknowledged. One limitation is that only English-language articles were searched and included. The meta-analysis conducted for hypoglycemia should be interpreted with caution because of high heterogeneity in defining hypoglycaemic events, an inherent problem when conducting metaanalyses in diabetes. 40 Of the 15 studies identified by the systematic review, the definitions of hypoglycaemia varied considerably (Table S5 , Supporting Information). With the exception of the study by Davies et al. 30 which required only the presence of symptoms for a hypoglycaemic event to be reported, the remaining studies did define a hypoglycaemic event using a blood glucose target, but this target varied between 3.0 and 4.0 mmol/L depending on the study.
Interpretation of findings from the meta-analysis of hypoglycaemia was further complicated by heterogeneity among studies with regard to background therapies and insulin titration; as such, future trials with similar background therapies, insulin titration algorithms and standardized definitions of hypoglycaemia are warranted for comparability of studies.
In conclusion, the current analysis indicates that once-weekly However, clarity and consistency is required in defining hypoglycaemia in clinical trials, to allow meaningful conclusions to be inferred for this outcome when comparing GLP-1 RAs with basal insulin.
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